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Induced pluripotent stem cells as tools for disease modelling and drug discovery
in Alzheimer's disease
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that leads to a progressive
decline in a person’s memory and ability to communicate and carry out daily activities. The brain
pathology in AD is characterized by extensive neuronal loss, particularly of cholinergic neurons,
intracellular neurofibrillary tangles composed of the tau protein (NFTs) and extracellular deposition of
plaques composed of β-amyloid (Aβ), a cleavage product of the amyloid precursor protein (APP). These
two insoluble protein aggregates are accompanied by a chronic inflammatory response and extensive
oxidative damage. Whereas dys-regulation of APP expression or processing appears to be important for
the familial, early-onset form of AD, controversy exists between the “Baptists” (in favour of Aβ) and the
“Tauists” (in favour of tau) as to which of these two protein dysfunctions occur at the earliest stages or
are the most important contributors to the disease process in sporadic AD. However, more and more
“non-amyloid” and “non-tau” causes have been proposed, including, glycation, inflammation, oxidative
stress and dys-regulation of the cell cycle. However, to get an insight into the ultimate cause of AD, and to
prove that any drug target is valuable in AD, disease-relevant models giving insight into the pathogenic
processes in AD are urgently needed. In the absence of a good animal model for sporadic AD, we propose
in this review that induced pluripotent stem cells, derived from dermal fibroblasts of AD patients, and
differentiated into cholinergic neurons, might be a promising novel tool for disease modelling and drug
discovery for the sporadic form of AD.
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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that
leads to a progressive decline in a person’s memory and ability to communicate and
carry out daily activities. The brain pathology in AD is characterized by extensive
neuronal loss, particularly of cholinergic neurons, intracellular neurofibrillary tangles
composed of the tau protein (NFTs) and extracellular deposition of plaques
composed of β-amyloid (Aβ), a cleavage product of the amyloid precursor protein
(APP). These two insoluble protein aggregates are accompanied by a chronic
inflammatory response and extensive oxidative damage. Whereas dys-regulation of
APP expression or processing appears to be important for the familial, early-onset
form of AD, controversy exists between the “Baptists” (in favour of Aβ) and the
“Tauists” (in favour of tau) as to which of these two protein dysfunctions occur at the
earliest stages or are the most important contributors to the disease process in
sporadic AD. However, more and more “non-amyloid” and “non-tau” causes have
been proposed, including, glycation, inflammation, oxidative stress and dysregulation of the cell cycle. However, to get an insight into the ultimate cause of AD,
and to prove that any drug target is valuable in AD, disease relevant models giving
insight into the pathogenic processes in AD are urgently needed. In the absence of a
good animal model for sporadic AD, we propose in this review that induced
pluripotent stem cells (iPSCs), derived from dermal fibroblasts of AD patients, and
differentiated into cholinergic neurons, might be a promising novel tool for disease
modelling and drug discovery for the sporadic form of AD.
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1. Alzheimer’s disease
1.1 Alzheimer’s disease and the urgent need for early diagnosis and specific
treatments
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that
leads to progressive decline in a person’s memory and ability to learn, make
judgments, communicate and carry out daily activities. In the course of the disease,
episodic memory is affected early, caused by neuronal dysfunction and cell death in
the hippocampus and other medial temporal structures. As the disease progresses
further, neurons also die in other cortical regions of the brain (Arendt 2009). At that
stage, sufferers develop abnormalities in a range of cognitive domains as well as
neuropsychiatric symptoms such as apathy, agitation or psychotic symptoms (Aalten
et al. 2008). Patients with AD not only suffer emotionally and physically, but also
represent a significant financial and emotional burden for caregivers, society and the
community. Thus, it is becoming increasingly important to find the initial cause(s) of
AD.
Induced pluripotent stem cell (IPSC) technology, whereby a patient’s somatic cells
can be reprogrammed to a pluripotent state by the forced expression of a defined set
of transcription factors, may offer a way forward to the development of novel
personalized neuroprotective therapies that prevent AD (Huber et al. 2006;
Holmquist et al. 2007; Maczurek et al. 2008). In addition, a growing focus is on
biomarkers which enable detection of the disease in its early stages and will allow for
preventative treatment (Song et al. 2009).
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1.2 Histopathology of Alzheimer’s disease – key to pathogenesis and therapy?
The brain pathology in AD that is associated with cognitive decline and profound
dementia is characterized by extensive neuronal loss, particularly of cholinergic
neurons, intracellular neurofibrillary tangles (NFTs) and extracellular deposition of βamyloid (Aβ) plaques (Braak et al. 2004; Thal et al. 2006). These two insoluble
protein aggregates accumulate in susceptible regions of the brain and are
accompanied by a chronic inflammatory response and extensive oxidative damage
(Sastre et al. 2006; Weisman et al. 2006; Fuller et al. 2010).
Senile plaques, composed of crosslinked (e.g. by glycation or oxidation) β-amyloid
(Aβ) peptide, are present in specific brain regions of AD patients (Loske et al. 2000;
Thal et al. 2002). Aβ has been proposed to have a variety of toxic properties such as
the ability to block communication between neurons, to cause degeneration of
neurites, to contribute to oxidative stress and ultimately to lead to neuronal cell death
(Kuhla et al. 2004). In addition, Aβ causes inflammation, as evidenced by the
activation of the inflammatory cells of the brain, microglia and astroglia, mainly
around the amyloid plaques (Wong et al. 2001).
The second protein aggregation problem in AD is largely intracellular, and results
from the deposition of neurofibrillary tangles in neurons. These tangles are mainly
composed of the cytoskeletal protein tau, and it has been suggested that hyperphosphorylation and glycation contribute to their insolubility (Chen et al. 2004). In the
CNS, tau is found in greatest abundance in neurons, where it stabilises microtubules
and is therefore key to maintenance of axonal integrity. Hyper-phosphorylation leads
to “neurofibrillary tangles”, destabilisation of the cytoskeleton, axonal degeneration
and eventually neuronal cell death (Goedert et al. 1995; Gotz et al. 2010). Recent
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studies suggest, that tauopathy in sporadic Alzheimer’s disease may begin in the
third decade and possibly starts in the lower brainstem rather than in the
transentorhinal region (Braak et al. 2011).
Considerable controversy still continues amongst the “Baptists”, and the “Tauists”
(favouring either amyloid or tau as the major contributor to the disease, respectively)
as to which of these two protein dysfunctions occurs at the earliest stages or are the
most important contributors to the disease process. In addition, more and more “nonamyloid” and “non-tau” causes have been proposed, including disturbances in the
insulin / insulin receptor glycation, inflammation, oxidative stress and dys-regulation
of the cell cycle. Detailed descriptions of these “non-amyloid” and “non-tau” causes
have been published in extensive reviews by the group of Peter Riederer and his
collaborators (Thome et al. 1996; Münch et al. 1997; Münch et al. 1998; Retz et al.
1998; Riederer et al. 2006; Arendt et al. 2010; Rahmadi et al. 2011; Srikanth et al.
2011).

1.2.1 Anti-amyloid drugs
The most favoured hypothesis about the cause of AD is the ‘amyloid cascade
hypothesis’. This hypothesis states that the aberrant production, aggregation and
deposition of Aβ is the causative process in the pathogenesis of both familial and
sporadic (late-onset) AD (FAD and LOAD) (Iwatsubo et al. 1994; Karran et al. 2011).
Aβ is a proteolytic fragment of the amyloid precursor protein (APP). In the
amyloidogenic pathway, APP is first cleaved by β-secretase (BACE1) to generate a
slightly shorter N-terminal ectodomain, APPs-β (Borchelt et al. 1996; Scheuner et al.
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1996; Tomita et al. 1997). This is then cleaved by γ-secretase within the
transmembrane domain to generate Aβ peptides of 40- and 42 amino acids in length
(Gotz, Lim et al. 2010) .
The view that Aβ plays a central role in AD pathogenesis has developed from
observations that patients with mutations in the APP and presenilin (PSEN) genes
show both accelerated plaque deposition and the onset of dementia at an early age,
and that all these patients demonstrate an increase in the production of Aβ,
particularly the longer and more aggregation prone Aβ 1-42 (Butterfield et al. 2002).
Based on the “amyloid cascade hypothesis”, there was great hope to find a cure for
AD by lowering the concentration of Aβ using a variety of different therapeutic
approaches. Various “anti-amyloid drugs” targeting different pathways of Aβ42
production and/or aggregation have been developed and tested in clinical trials with
AD patients. Their mechanisms of action include:
-

Inhibiting the enzymatic actions of the secretases with β- and γ-secretase

inhibitors, thereby lowering the production of Aβ (Imbimbo et al. 2011)
-

Changing the action of the γ-secretase and changing Aβ production from β1-

42 to shorter amyloid chain lengths using amyloid modulators (Czirr et al. 2006)
-

Eliciting an anti-Aβ antibody response (active immunization) or providing

recombinant Aβ antibodies (passive immunization), both leading to amyloid removal
by the immune system (Münch et al. 2002; Robinson et al. 2004; Dasilva et al. 2006;
Panza et al. 2010).
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- Metal chelators which dissipate A plaque deposits by chelating divalent metal
ions (Fe2+, Cu2+ and Zn2+). A current example is clioquinol, with impressive effects in
transgenic, APP overexpressing animal models and interesting results in phase I and
II clinical trials (Bush 2002; Faux et al. 2010; Adlard et al. 2011; Bareggi et al. 2012)
Unfortunately, all “anti-amyloid drug” candidates have so far failed to produce the
expected therapeutic breakthroughs. They did, however, succeed in their effort to
lower amyloid production and/or to remove amyloid plaques, but the cognitive
decline in the treated patients did not slow down (Wan et al. 2009; Smith 2010;
Castellani et al. 2011).
These results suggest that Aβ might not be the dominant cause of sporadic AD (at
least in some patients), and the “anti-amyloid approach” may not be an effective
treatment for AD by itself, or may need to be given prophylactically (Golde et al.
2011).

1.2.2 Anti-tangle drugs
Tau, the protein component of the neurofibrillary tangles, is a microtubule-associated
protein. It is proposed that the neurofibrillary tangles are formed as a result of
abnormal hyper-phosphorylation, caused by an imbalance of kinase and
phosphatase activities (Goedert et al. 1995). A variety of kinases involved in the
hyper-phosphorylation of tau have been described. These include glycogen synthase
kinase-3 (GSK-3), mitogen-activated protein kinase (MAP)-kinase and microtubule
affinity-regulating kinase 1 (MARK1). In addition, an insufficient activity of protein
phosphatases, especially protein phosphatase 2A (PP2A), has also been suggested
to be responsible for hyper-phosphorylation of tau. Another approach to the inhibition
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of tangle formation might be the inhibition of tau crosslinking e.g. by advanced
glycation endproducts by the use of anti-glycation agents (Kuhla et al. 2007;
Krautwald et al. 2010; Rahmadi et al. 2011). Furthermore, it has been suggested that
microtubule (MT)-stabilizing drugs such as epothilone D (EpoD), which improve in
existing tau pathology and related behavioral deficits in aged PS19 mice, might hold
promise for the treatment of AD and related tauopathies
Inhibitors of kinases and activators of phosphatases are the main classes of “antitangle” drugs (Navarrete et al. 2011). Two “anti-tangle” drugs, the GSK-3 inhibitors
Tideglusib (Noscira, Spain) and the tau aggregation inhibitor methylthioninium
chloride, Rember (TauRx Therapeutics, Singapore), have been tested in phase II
clinical trials with some positive results, but the results of large phase II trials are still
outstanding.
However, with growing uncertainty of the therapeutic potential of drugs targeting
amyloid and tau, other novel therapies have recently been proposed, including those
targeting glycation, oxidative stress and inflammation (Retz et al. 1998; Maczurek et
al. 2008; Rahmadi, Steiner et al. 2011; Srikanth et al. 2011).
However, to get an insight into the ultimate cause of AD, and to prove that any drug
target is valuable in AD, disease relevant models giving insight into the pathogenic
processes in AD are urgently needed. In the absence of a good animal model for
sporadic AD, we propose in this review that induced pluripotent stem cells (iPSCs),
derived from dermal fibroblasts of AD patients, and differentiated into cholinergic
neurons, might be a promising novel tool for disease modelling and drug discovery
particularly for the sporadic form of AD. In the following sections, we will introduce
the concept of iPSCs and review recently published studies in which these cells were
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used for AD disease modelling, and yielded interesting, and sometimes unexpected
results.

2. Induced pluripotent stem cells (iPSCs) as a key to disease pathogenesis and
drug discovery

2.1

Introduction to induced pluripotent stem cells (iPSCs)

The discovery of induced pluripotent stem cells (iPSCs), whereby a patient’s somatic
cells can be reprogrammed to a pluripotent state by the forced expression of a
defined set of transcription factors, has the potential to enable in vitro disease
modelling and be used for drug discovery programs. In 2006, it was demonstrated
that retroviral-mediated introduction of four transcription factors into mouse
fibroblasts could convert them into cells closely resembling pluripotent embryonic
stem cells (ESCs)(Takahashi et al. 2006). In that study, Yamanaka and his group
found that the introduction of a combination of four transcription factors — octamer
binding protein 4 (also known as Pou5f1), Sox2, Krüppel-like factor 4 (Klf4) and cMyc — into mouse fibroblasts was sufficient to induce the expression of endogenous
pluripotency genes and thus reprogram the somatic cells to a new state with colony
morphology, cell morphology, growth characteristics, gene expression and antigen
expression similar to mouse ESCs. This stunning discovery was quickly replicated
using human somatic cells, with the Yamanaka and Daley groups employing
essentially the same gene cocktail (Takahashi et al. 2007; Park et al. 2008) and the
Thomson group using a slightly different one (i.e., OCT4, NANOG, SOX2 and LIN28)
(Yu et al. 2007). Further evidence that these reprogrammed cells are pluripotent
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was achieved by demonstrating they are capable of germ-line transmission in
chimeric mouse assays (Okita et al. 2007; Wernig et al. 2007). Importantly, this work
also showed that use of c-Myc should be avoided in reprogramming gene cocktails,
as reactivation of the exogenous c-Myc transgene can lead to tumour formation.
The ability to reprogram human somatic cells to a pluripotent state provides a means
to generate large numbers of patient-specific differentiated cells for both research
and transplantation. Equally important, this reprogramming technology also enables
the production of disease-specific cells from confirmed patients with disorders
without a clear pattern of inheritance (“sporadic” cases). Accordingly, our group and
others have generated hiPSCs from patients with sporadic AD. These new hiPSC
lines will enable investigation of the development and maintenance of cholinergic
neurons in a context uniquely-related to AD, with the potential for high-throughput
chemical screening to identify lead compounds for AD treatment (Fig. 1). In our
hands, colonies of AD-iPSCs were morphologically indistinguishable from control
(Co) iPSC and hESCs (Fig. 1A). Further characterization revealed that AD-iPSCs
were genetically and phenotypically indistinguishable from control hESC/hiPSCs.
Hypomethylated OCT4 promoter regions indicate successful reprogramming of ADFibs (24.4% vs. 66.7%, Fig. 1B). Using immunofluorescence staining, feeder-free
cultures of AD-iPSCs typically expressed undifferentiated pluripotent markers OCT4,
NANOG, SSEA4 and TRA160 (Fig. 1C). Quantitative gene expression analyses of
pluripotency-associated genes were not significantly different across all pluripotent
cell lines. In contrast, parental fibroblasts (AD-Fib) expressed extremely low levels of
NANOG, OCT4, SOX2 and GDF3, but had similar levels of CMYC and KLF4
expression (Fig.

1D). Furthermore, extended feeder-free culture showed no
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chromosomal abnormalities in ALZ1/ALZ7 as determined by standard G-banding
karyotypic analysis (Fig. 1E).
Although hiPSCs share key morphological and molecular characteristics with human
embryonic stem cells (O'Connor et al. 2011), genetic and epigenetic differences
have been identified (Bock et al. 2011; Nishino et al. 2011; Wang et al. 2011)
For example, the reprogramming process and/or subsequent culture can result in
random DNA alterations not present within the genome of the parent cell (Hayden
2011). Since random integration of the transgene might lead to clonal heterogeneity
and possible functional diversity, it is recommended to validate findings from one
hiPSC clone with multiple independently-derived hiPSC clones from the same
patient (Sidhu 2011).

2.2 Drug discovery for AD using iPSCs
Another potential challenge for both high-throughput drug screening and
developmental investigations of Alzheimer’s-specific hiPSC cell lines is the
production of large numbers of highly purified, mature cholinergic neurons.
Encouragingly, methods for differentiating and purifying cholinergic neurons from
hiPSC cultures have been published though it is presently unclear whether these
neurons are, or can be induced to become, fully mature (Israel et al. 2012).
A further challenge for hiPSC-based investigation of neurological disorders is that
these disorders manifest themselves within the complex 3-dimensional architecture
of the brain. This architecture is difficult to reproduce in vitro, leading to some
limitations with in vitro drug screening for novel neurological pharmaceuticals.
However, careful design of the drug screening assay parameters and detection
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methods should enable identification and pre-clinical validation of new lead
compounds that have the potential to at least delay, if not cure, progression of
diseases such as Alzheimer’s disease (Grskovic et al. 2011).
Although iPSC technology seems promising, several safety obstacles need to be
addressed before iPSCs transits to the clinic; in particular, the risk of insertional
mutagenesis when using integrative viruses and the transmission of pathogens when
in media and/or feeder layers containing animal products. While transgene/viral-free
methods have been developed, a majority of iPSCs are still derived on animal feeder
layers, which offsets the benefits of a xeno-free autologous transplantation. The use
of animal feeder layers also introduces inconsistent and variable reprogramming
outcomes, making the screening of suitable, fully reprogrammed iPSC colonies labor
intensive (Chan et al. 2009). This is reflected in iPSC lines generated under different
experimental conditions and show varying degrees of differentiation into
hematopoietic and neural lineages (Feng et al. 2010; Hu et al. 2010), which also
limits its therapeutic potential. The use of defined media however, minimizes variable
and/or inhibitory components present in serum and growth-factor secreting feeder
cells. Consequently, some laboratories have generated iPSCs under feeder-free
conditions by using extracellular matrices and serum-free media (Sun et al. 2009;
Vallier et al. 2009; Vallier et al. 2009). While the phenotypic outcomes have been
tested, transcriptomic characterization of feeder-free derived iPSCs has not been
fully explored. The advent of whole transcript gene expression microarrays was
capitalized on to identify underlying molecular events that may underpin the
differences between feeder-derived, feeder-free derived iPSCs and human
embryonic stem cells (hESCs) propagated under identical conditions. We for the first
time reported that feeder-free iPSCs (ff-iPSCs) resemble hESCs more than feeder
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derived iPSCs (f-iPSCs) in terms of overall gene expression patterns governing
pluripotency and other biological functions. The processes related to pluripotent
signature in hESCs (ie, DNA replication and cell cycle) were substantially enriched in
ff-iPSCs and expression of bivalent genes was lower (Chung et al. 2012). The
advantages of a feeder-free defined system are such that homogenous populations
of patient-specific pluripotent stem cells can be generated, batch-to-batch
differences created by serum and feeder-cells can be eliminated and scale-up
cultures can be easily carried out. This is of particular interest in regenerative
medicine.

2.3 AD disease modelling with iPSCs – identification of differences in cell
phenotype and specific, AD-related cellular processes
The key to modelling any human disease is the identification of a disease-specific
unique cellular phenotype. The most successful examples of this strategy have used
diseases that have strong genetic components and affect a highly defined cell type
leading to a characteristic difference to an unaffected cell, e.g. for diseases with a
known molecular mechanism, such as in spinal muscular atrophy, HutchinsonGilford Progeria syndrome, familial Parkinson’s disease or Down syndrome (Ebben
et al. 2011; Malpass 2011; Jung et al. 2012; Shi et al. 2012).
Similarly, iPSCs have been created from patients with familial AD (FAD)
characterized by mutations in APP, PSEN1 and PSEN2. For example, Yagi et al.
generated iPSCs from fibroblasts of AD patients with mutations in PSEN1 (A246E)
and PSEN2 (N141I), and characterized their subsequent differentiation into neurons
(Yagi et al. 2011). They found that FAD–iPSC-derived neurons showed increased
Aβ42 secretion. Furthermore, secretion of Aβ42 from these neurons sharply
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responds to γ-secretase inhibitors and modulators, indicating the potential for
identification and validation of amyloid-lowering drugs (Yagi, Ito et al. 2011; Yahata
et al. 2011).
In a further study, it was shown that iPSC-derived neuronal cells express functional
proteins involved in Aβ production, including amyloid precursor protein, β-secretase,
and γ-secretase, and were capable of secreting Aβ into the conditioned media
(Yahata, Asai et al. 2011). Although Aβ production was inhibited by β- and γsecretase Inhibitors and an NSAID, there were different susceptibilities to all three
drugs between early and late differentiation stages (Yahata, Asai et al. 2011).
In another study, Israel et al. created iPSCs from two patients with familial AD, both
caused by a duplication of the amyloid-precursor protein gene (APP ; termed
APPDp), two with sporadic AD (termed sAD1, sAD2) and two non-demented controls
(Israel, Yuan et al. 2012). They showed that relative to controls, iPSC-derived,
purified neurons from the two APPDp patients and patient sAD2 exhibited
significantly higher levels of the pathological markers Aβ(1–40), phospho-tau (Thr
231) and active glycogen synthase kinase-3 β. Neurons from these patients also
accumulated large RAB5-positive early endosomes compared to controls, indicating
an impairment of autophagy. Interestingly, they also showed that treatment of
purified neurons with β-secretase inhibitors, but not γ-secretase inhibitors, caused
significant reductions in phospho-Tau (Thr 231) and GSK-3β levels (Israel, Yuan et
al. 2012).
Encouragingly, methods for differentiation and purifying cholinergic neurons from
hiPSC cultures have been published though it is presently unclear whether these
neurons are, or can be induced to become, fully mature ”. Israel et al described in
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their manuscript that differentiated and purified neurons contained glutamatergic,
GABAergic and cholinergic neuronal subtypes (Israel, Yuan et al. 2012). However,
the two manuscripts about AD-iPSCs disease modelling did not contain descriptions
about validated differentiation methods for pure cultures of cholinergic neurons
(Yagi, Ito et al. 2011; Israel, Yuan et al. 2012). However, protocols published
describing the differentiation of ESCs to cholinergic neurons might provide useful for
the cholinergic differentiation of iPSCs (Bissonnette et al. 2011).
These two studies demonstrate that iPSC technology can be used to observe patient
specific phenotypes in vitro, which reflect both the familial and the sporadic forms of
the disease in a remarkable manner.

2.4 AD disease modelling with iPSCs – mapping differences in gene and
protein expression
Both Yagi et al. and Israel et al. used protocols that induce differentiation to multiple
neuronal subtypes (Yagi, Ito et al. 2011; Israel, Yuan et al. 2012). However, in the
early stages of AD there is a preferential loss of cholinergic neurons and their
innervation of the hippocampus and neocortex (Schliebs et al. 2011).
One of the most interesting questions is whether the neurons derived from iPSCs of
AD patients can be differentiated into cholinergic neurons, by activating specific
intracellular signalling pathways including repressor element 1-silencing transcription
factor (REST) and its corepressor (CoREST) (Ooi et al. 2007). Furthermore, it will be
interesting to find out if AD iPSCs are distinctly different from those from age and
gender-matched healthy controls in terms of global expression of mRNA and protein.
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The induction of pluripotency largely revert somatic cells to their embryonic or
‘ground’ state. Using a developmental approach and disease-related perturbations or
stressors, the life history of the disease can be recapitulated in vitro from iPSCs
creating differentiable phenotypes. The alternative approach of culturing adult stem
cells without a pluripotent stage would certainly maintain epigenetic cellular memory
but it would be subsequently difficult to separate disease ‘cause’ from ‘effect’ (Murrell
et al. 2008; Valenzuela et al. 2008).

Similarly, the direct reprogramming of

fibroblasts to neurons is likely to retain this ‘cell memory’ (Vierbuchen et al. 2010;
Qiang et al. 2011).

However, there are also limitations and drawbacks on the use of iPSCs for dsease
modelling and drug discovery. One of the limiting factors in the utility of iPSC lines
for drug discovery and safety is the considerable technical ‘noise’ obscuring the
disease-related ‘signal’. A major contributor to this noise is the lack of consistency
and poor target cell enrichment during iPSC differentiation. However, our feeder-free
system for generating iPSCs offers a robust system for obtaining a homogeneous
population of these cells that follow pluripotent signature patterns (Chung, Lin et al.
2012). The other key paradigm to circumvent the poor signal problem, which may
then be tailored to the disease could be stratification of samples based on genetics
(monogenic vs. polygenic/sporadic) and clinical history (responders vs. nonresponders). A further problem is the large clonal variation of iPSCs, which requires
the generation of a couple of clones from each patient and comparison of properties
among these different clones to prove a general biological characteristic of the
patient.
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3. Outlook – personalised medicine for AD patients
The use of iPSC cellular models is therefore likely to lead to novel insights into the
pathogenesis of AD, and to help discover new drugs for its treatment and/or
prevention. Since these models are derived from individual patients, the cellular
characteristics can be related to clinical features of the disease in that patient. An
individual’s variations in the disease process and their cellular response to drugs
may be reflected in the cellular model. If this is shown to be the case, a patient’s
treatment regimen in the future could conceivably be individualised, based on the
behaviour of the cellular model. For example, in the study by Israel et al only 1 out of
the 2 sporadic AD patients showed similarities to familial AD cell lines in terms of
amyloid production, phospho-tau and active glycogen synthase kinase-3β levels
(Israel, Yuan et al. 2012), suggesting aetiological heterogeneity in the sporadic
cases with a potential for differential treatment.
Defining AD subgroups with iPSC technology presents an excellent opportunity for a
true personalised approach to the treatment of AD. However, using current
reprogramming and differentiation technology, it is unlikely that generating individual
neurons from hiPSC for every patient for treatment will be economically viable. It is
more likely that use of newly derived AD-hiPSCs will enable in vitro disease
modelling that then enables patient specific therapies based upon appropriate
characterisation of AD patient groups by genetics and biomarker profile, and
subsequent appropriate, targeted drug treatment.
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Figure 1. Characterization of Alzheimer’s disease specific hiPSCs (AD-iPSCs).
A) Colony morphologies of hiPSCs from a non-demented control (Co-iPSC) and a
sporadic AD patient (AD-IPSC) under feeder-free conditions. Scale = 500 µm. B)
OCT4 promoter DNA methylation analysis using bisulfite sequencing. (Open
squares: unmethylated, closed squares: methylated). C) Immunofluorescence
staining of typical undifferentiated Co-hiPSCs;nuclear/surface markers, OCT4,
NANOG, TRA160, SSEA4. Scale = 200 µm. D) Gene expression analyses of
pluripotency-related gene of a non-demented control (Co-iPSC), two sporadic AD
patients (ALZ1 and ALZ 27), and the original AD fibroblast cultures (AD-Fib) using
quantitative PCR. *** p< 0.0005 E) Standard G-banding karyotypic analysis of ADiPSCs after extended propagation under feeder-free conditions.
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